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Vitamin D3 (cholecalciferol), the natural form 
of vitamin D, is produced in the skin from 7-
dehydrocholesterol. Upon irradiation, 7-
dehydrocholesterol produces pre-vitamin D3 which 
undergoes a temperature-sensitive rearrangement of 
three double bonds to form vitamin D3. The synthesis of 
vitamin D in the skin is the most important source of 
vitamin D. Vitamin D can also be taken through nutrition, 
in the diet, but it is present in only a few food sources, 
such as little number of fish species, containing relevant 
levels of vitamin D. Vegetarian diet is limited to the plant 
vitamin D2 that is only present in some mushrooms. 
Commercially dark cultivated white button mushrooms 
contain low amounts of vitamin D2, only wild 
mushrooms or sun-dried mushrooms contain elevated 
amounts of ergocalciferol [1].  
Vitamin D3 assumes its biological activity by 
binding with DBP (Vitamin D binding protein), which 
transports vitamin D and its metabolites from blood 
serum to the liver. Where vitamin D is hydroxylated at 
C-25 to produce its major circulating form – 25-
hydroxyvitamin [2].  The 25-hydroxyvitamin D3 needs to 
be further hydroxylated to form 1,25-dihydroxyvitamin 
D3. Major sites for conversion of 25(OH)D3 to 
1,25(OH)2D3 are kidney and placenta [3]. 
1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the 
hormonally active form of vitamin D. Novel researches 
show it generates a number of extraskeletal biological 
responses including inhibition of variety types cancer 
progression, effects on cardiovascular disorders and 
mediates a protection against a number of inflammatory, 
autoimmune and infection diseases [4]. 
The biological actions of 1,25(OH)2D3 are 
mediated by the VDR. VDR is a polymorphic nuclear 
receptor and belongs to the steroid receptor family which 
includes receptors for retinoic acid, thyroid hormone, sex 
hormones, and adrenal steroids [5]. The heterogeneous 
loss of function mutations in the VDR caused the 
1,25(OH)2D3 organ resistance and leads to Hereditary 
vitamin D-resistant rickets [6]. The genomic mechanism 
of 1,25(OH)2D3 action involves the direct binding of 
1,25(OH)2D3 activated VDR/RXR to specific DNA 
sequences [vitamin D response elements (VDREs)] in 
and around target genes resulting in either activation or 
repression of transcription [7]. In this way more than 
1000 genes are regulated by Vitamin D through the 
VDR [8]. VDR modulates the expression of genes 
involved in immune function and cytokine production. 
The VDR and CYP27B1, the enzyme located in kidneys 
and target organs, are present in immune competent cells, 
bronchial and pulmonary epithelial cells, among others, 
and is up-regulated following the ligation of specific toll-
like receptors by extracellular pathogens, implicating 
vitamin D in innate immunity [9-14]. 
By binding the VDR, calcitriol induces several 
endogenous antimicrobial peptides (AMP) in monocytes, 
neutrophils and epithelial cells including cathelicidin LL-
37, α-defensin, β defensing and neutrophil gelatinase-
associated lipocalin and up-regulates nitric oxide (NO) 
synthase [15-18]. AMPs inhibit infection caused by 
bacteria, viruses and fungi, while NO synthase augments 
bacterial killing by up-regulating the oxidative burst in 
activated macrophages [19-22]. Vitamin D may also 
induce a Th2-based response, characterized by high 
Immunoglobulin IgE and eosinophilia, to combat 
extracellular infections caused by parasites, protozoa and 
fungi. In addition to its role in innate immunity, calcitriol 
suppresses pro-inflammatory cytokines in vitro and in 
vivo, and up-regulates anti-inflammatory cytokines, such 
as IL10 [23-27]. Since the inflammatory response 
associated with infections such influenza, pneumonia and 
sepsis increases both clinical severity and mortality, the 
ability to reduce inflammation may allow vitamin D to 
decrease mortality and disease burden in certain 
infections [28-31]. 
Notwithstanding the width of possible vitamin 
D application field, which being known now, large-scale 
clinical trials are still demanded. 
Our review has the aim to summarize current 
scientific understanding of Vitamin D3 effects on the 
immunological field with the focus on its capacity to 
enhance the anti-infection and anti-inflammatory 
immune reactivity. 
 
Vitamin D – the innate and adoptive immunity 
modulator. 
In a cross-sectional analysis serum 25(OH)D 
levels were found to be significantly lower in critically ill 
septic patients. This was associated with decreased 
concentrations of the antimicrobial protein cathelicidin 
[32]. This finding supports the theory that the vitamin D 
status regulates antimicrobial protein levels of innate 
immune cells and may be crucial in infection control. 
Dendritic cells (DC) are also important targets for the 
immune modulatory effects of vitamin D. Different 
studies have shown that calcitriol and its analogs can alter 
function and morphology of DC to induce a more 
tolerogenic, immature state [33-36]. Immature DC are 
characterized by decreased levels of MHC class II and 
co-stimulatory molecule expression (CD40, CD80, 
CD86), which leads to reduced antigen presentation 
accompanied by a lower IL12 secretion but an increased 
production of the tolerogenic interleukin IL10. Calcitriol 
has also been described to inhibit T cell cytokines such 
as IL2 and IL17 and toll like receptors on monocytes 
[37]. High-dose calcitriol supplementation in healthy 
humans (1 μg twice daily for 7 days) leads to a significant 
reduction of the proinflammatory cytokine IL6 produced 
by peripheral mononuclear cells [38]. It is likely that a 
combination of these effects results in the induction of 
potential regulatory T cells which are crucial for 
controlling immune responses [39]. In vitro data are also 
supported by results from VDR and CYP27B1 knockout 
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mice which show significantly increased numbers of 
mature DC and abnormal DC chemotaxis [40]. 
Early studies of vitamin D effects on human 
adaptive immune cells demonstrated an expression of the 
nuclear VDR as well as vitamin D-activating enzymes in 
both T- and B cells [41]. Actually, VDR expression by 
these cells is very low in resting conditions but upon 
activation and proliferation, T- and B cells up-regulate 
VDR expression significantly, allowing regulation of up 
to 500 vitamin D responsive genes which influence 
differentiation and proliferation. In B cells, 
antiproliferative effects of vitamin D3 such as inhibition 
of differentiation, proliferation, initiation of apoptosis 
and decreased immunoglobulin production were initially 
considered to be exclusively indirectly mediated by CD4+ 
cells [42]. More recent studies confirmed additional 
direct effects of vitamin D3 on B cell function, including 
inhibition of memory- and plasma-cell generation, as 
well as promotion of immunoglobulin-producing B cells 
apoptosis [43]. This control on B cell activation and 
proliferation may be clinically important in autoimmune 
diseases as B-cells producing autoreactive antibodies 
play a major role in the pathophysiology of 
autoimmunity. 
T cells, is also thought to be an important target 
for the immune modulatory effects of vitamin D different 
forms. Four potential mechanisms by which vitamin D 
may influence T cell function have been proposed. There 
are direct, endocrine effects on T cells mediated via 
systemic calcitriol; direct, intracrine conversion of 
25(OH)D to calcitriol by T cells; direct, paracrine effects 
of calcitriol on T cells following conversion of 25(OH)D 
to calcitriol by monocytes or dendritic cells and indirect 
effects on antigen presentation to T cells mediated via 
localized APC affected by calcitriol [44]. Vitamin D 
exposure leads to a shift from a proinflammatory to a 
more tolerogenic immune status, including very diverse 
effects on T cell subtypes. Thus, vitamin D3 suppresses 
CD4+ cell proliferation, differentiation and modulates 
their cytokine production [45]. In particular, treatment of 
T cells with calcitriol or analogs inhibits the secretion of 
proinflammatory Th1 (IL2, IFN-γ, TNFα), Th9 (IL9) and 
Th22 (IL22) cytokines [46-48], but promotes the 
production of more anti-inflammatory Th2 cytokines 
(IL3, IL4, IL5, IL10) [49]. IL17 producing Th17 cells are 
also affected by vitamin D. Recently, calcitriol was found 
to directly suppress IL17 production on a transcriptional 
level and activated human T-cells exposed to calcitriol 
produced significantly decreased levels of IL17, 
interferon-γ and IL21 [50, 51]. The same study also 
revealed a change towards a tolerogenic phenotype, 
including increased expression of genes typical for 
regulatory T cells (Tregs), by adding a combination of 
calcitriol and IL2 to human primary T cell cultures. Tregs 
act to suppress proinflammatory responses by other 
immune cells and aim to prevent exaggerated or 
autoimmune responses [52]. Tregs can be induced and 
stimulated by vitamin D in an indirect pathway, via APC, 
including the group of DC which stay in an immature 
state upon vitamin D treatment and therefore present less 
antigens. The direct pathway acts via systemic calcitriol 
effects or intracrine conversion of 25(OH)D to calcitriol 
by Tregs themselves. Administration of calcitriol to renal 
transplant recipients expanded the circulating Treg 
population [53]. In the subsequent randomized, placebo 
controlled trial in healthy subjects, the percentage of 
Tregs in peripheral blood increased significantly after 
supplementation with high doses of cholecalciferol [54, 
55]. Using cholecalciferol supplementation as adjunctive 
therapy in new onset T1D patients, the percentage of 
peripheral Tregs increased, although there was no 
significant difference in Tregs percent between placebo 
and treatment group after 1 year of supplementation [56]. 
These results suggest that vitamin D may 
support the innate and adaptive immune system and 
could also provide a safe and useful future therapy to 
support immune tolerance in autoimmune diseases or 
following transplantation. 
 
Vitamin D3 supplementation 
Though some prospective studies suggest that 
vitamin D plays a positive role in various infectious 
processes including tuberculosis, influenza and HIV, 
chronic obstructive pulmonary disease exacerbations and 
sepsis [57-59].  
The last 10 years of vitamin D application trials 
are focused on its role in various pulmonary diseases. A 
majority of these researches studied respiratory tract 
infections and exacerbations linked to them, pneumonia 
and tuberculosis. 
The placebo, randomized, double blind, single 
center trial (280 postmenopausal women) that started in 
2007 and continued for 3 years shows that 
supplementation of vitamin D3 in a daily dose 800 IU for 
2 years and 2000 IU for 1 year decreased cold and 
influenza symptoms and self-reported respiratory tract 
infections [60].  
Another placebo, randomized, double blind, but 
multicenter trial (430 healthy children) started in 2010 
suggested that daily implication of vitD3 (1,200 IU) for 
3 month leads to the decreasing of influenza A incidence 
and asthma attacks in children with asthma [61]. Majak 
in not very wide placebo, randomized, double blind, 
single center research (48 children with new asthma) 
shows that daily 500 IU of D3  for 6 month helps to 
increase lung function, minimize the score of asthma 
symptoms and number of asthma exacerbations due to 
respiratory tract infection [62].  
Bergman in 2012 in placebo, randomized, 
double blind, single center trial proposed 4000 IU of D3 
daily for 1 year to 140 participants with an antibody 
deficiency or participants who have had more than 4 
respiratory tract infection episodes during the year. This 
scheme helps to decrease the rate of infection and number 
of days on antibiotics by 50 % [63]. Camargo in 2012 
successfully used daily D3 in a dose 300 IU to 247 
healthy ~ 10 years-old children for minimizing 
respiratory tract infection episodes [64]. In patients with 
moderate to very severe chronic obstructive pulmonary 
disease implication of 100,000 IU of vitamin D3 with 
monthly intervals resulted in improvement in lung 
function, rates of exacerbation, morbidity and mortality, 
although positive results were limited to participants who 
were vitamin D deficient at baseline [65]. Cystic fibrosis 
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patients who received a single 250,000 IU dose of 
vitamin D3 while hospitalized experienced a significant 
increase in hospital-free days during the year and 50,4 % 
decrease in TNFα concentrations up to 12 weeks [43]. 
 
Vitamin D and Tuberculosis 
Vitamin D has been widely studied in the 
prevention and treatment of tuberculosis. Current studies 
were focused on how calcitriol enhances the 
antimicrobial effects of macrophages and monocytes – 
important effector cells, fighting against pathogens such 
as Mycobacterium tuberculosis (MBT). Besides 
enhancing chemotaxis and phagocytic capabilities of 
innate immune cells [66], the complex of calcitriol, VDR, 
and retinoid X receptor directly activates the 
transcription of antimicrobial peptides such as defensin 
β2 (DEFB) and cathelicidin antimicrobial peptide 
(hCAP18) [67-69]. In detail, monocytes exposed 
to MBT show a strong induction of the 1α-hydroxylase 
CYP27B1 and the vitamin D receptor after recognizing 
pathogens by toll-like receptors, leading to a direct 
modulation of gene expression, favoring production of 
cathelicidin [70]. Besides TLR-signaling, other cytokines 
such as interferon-γ or IL-4 have been found to also effect 
CYP27B1 expression [71]. Human cathelicidin 
(hCAP18) which is cleaved from LL-37 (37-residue 
active cationic peptide) and then causes destabilization of 
microbial membranes, is up-regulated in response to 
infections in humans and also acts against bacteria, 
viruses and fungi [19]. 
Several studies tracked the impact of vitamin D 
on cytokines that promote anti-MTB activity and the 
resolution of infection. Suppression of antigen-
stimulated pro-inflammatory cytokines, attenuation of 
anti-inflammatory cytokines, and a more rapid treatment-
induced resolution of lymphopenia and monocytosis 
associated with TB infection occurred following 100,000 
IU doses of vitamin D3 given monthly for 4 
months [72].The trial that studied tuberculosis (TB) 
prevention showed a single dose of 800 IU of vitamin 
D3 to cause a significant increase in anthropometric 
measurements and a 59 % reduction in tuberculin skin 
test conversion rates when given to children for 6 
weeks [73]. Some papers discussed vitamin D both as an 
adjunct to antibiotic treatment for TB and in its ability to 
direct killing of MBT [74-76]. Vitamin D implication led 
to clinical improvements in several studies, including: 
weight gains (in adults who received two doses of 
600,000 IU of vitamin D3 and children received daily 
doses of 1000 IU for 8 weeks [76, 77], less tissue 
involvement was observed after 1,000 IU daily use 
during 2 months and chest x-ray after 5,000 IU of vitamin 
D3 daily for 3 months. Conversely, no improvement on 
x-ray was seen in children receiving daily doses of 
vitamin D (1,000 IU over 2 months [77] or adults 
receiving daily of 10,000 IU for 6 weeks [78] or monthly 
implication of 50,000 IU given twice doses of vitamin D3 
[79].  
Conversion of sputum smear or sputum culture 
was used to measure response to treatment in several 
studies, though only sputum culture conversion is 
independently linked to long-term risk of treatment 
failure and relapse [80]. Also it was found [78] that 
10,000 IU of vitamin D3 given daily for 6 weeks to 
significantly increase sputum smear conversion (100 % 
in the treatment group vs. 76,7 % in the placebo group, 
p=0,002). 
IFN-γ levels were impacted variably: 2 doses of 
vitamin D3  (600,000 IU)) led to increasing of IFN-γ 
expression [76], while a single 100,000 IU dose of 
vitamin D2 showed no change [75].  
In the result of another trial (95 patients) was no 
effect on time to sputum culture conversion after 
adjusting for multiple baseline factors (35 vs 46,5 days, 
p≤0,05), but vitamin D accelerated normalization of 
erythrocyte sedimentation ratio and serum C-reactive 
protein in this population. Vitamin D also reduced 
chemokine production, but it had no effect on IFN-γ [72]. 
Two studies evaluated vitamin D in combination 
with another chemical thought to modulate activity 
against MTB; 5,000 IU of vitamin D3 given for 4 days 
alone or in combination with phenylbutyrate induced 
both circulating levels and transcript expression of the 
anti-microbial peptide LL-37 [81], while 50,000 IU 
doses with or without l-arginine (for NO production 
promotion) showed no significant change in sputum 
culture conversion rate or x-ray involvement [79].  
Negative results in some studies could be 
explained by variability of the Taq1 vitamin D receptor 
genotype polymorphism. It was shown that significantly 
accelerated conversion is appropriate of patients who 
have a tt genotype compared to those with 
the Tt or TT genotype. 
Thus one study reported a significant benefit of 
vitamin D evident in 12 subjects with the tt Taq1 VDR 
genotype, with proportions culture positive at week 8 of 
0 % and 57 % in the vitamin D and control arms, 
respectively [75]. There was no benefit of vitamin D in 
other VDR genotypes. These results were not confirmed 
by the study, where were founded no effect of VDR 
genotype on vitamin D in an analysis that included 30 tt 
genotype subjects. In this trial was carried out a subset 
analysis in 18 patients who were found after enrollment 
to have multidrug-resistant-tuberculosis. Treatment with 
second-line drugs began after a mean of 51 days for 
placebo recipients and 62 days for vitamin D recipients. 
Six of 10 recipients remained culture positive at week 8 
in the placebo arm versus 1 of 8 in the vitamin D arm 
[75]. 
As a resume, vitamin D given largely as an 
adjunctive therapy with traditional anti-tuberculosis 
regimens in a variety of dose and dosing schedule has 
some impact on clearance of M. tuberculosis from 
sputum in the wide number randomized controlled 
multicenter trials of patients with active tuberculosis 
infection. Patients with infection of MBT with different 
strains of tuberculosis can take benefits from Vitamin D3 
consumption due to its effect on the clearance of MTB 
from sputum and on dampening the inflammatory 
response or anthropometric changes that may help 
tuberculosis patients recover. A significant 
microbiologic effect of vitamin D3 was indicated in 
several trials that, also, sustained by in vitro tests, where 
its antimycobacterial effects in cultured macrophages 
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was shown. Antimycobacterial effect is provided 
enhances the expression of the anti-microbial peptide 
human cathelicidin (hCAP18) in cultured macrophages 
[82]. The clinical benefit after high vitamin D3 doses 
administrating to patients does not depend of their 
vitamin D3 marked deficiency. The cause of this variation 
remains unexplained. The Role of genetic 
polymorphisms in the vitamin D receptor, or in the 
multiple enzymes involved in its metabolism in vitD3 
effectiveness remains unproved. Measurement of 
calcitriol-induced antimycobacterial activity in ex vivo 
whole blood culture in future studies may help in 
understanding the functional effects of specific genetic 
polymorphisms. So, big attention will be required in 
future studies to determine mechanism of vitamin effect 
on patients with tuberculosis. 
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VITAMIN D3: RESEARCH BREAKTHROUGHS 
AND THERAPEUTIC USE 
Pohorila М.S., Martynov A.V., Romanova E.А., 
Іgumnova N.І., Sidorenko Т.А., Yukhimenko V.І., 
Shcherbak O.M. 
Vitamin D3 (cholecalciferol), the natural form of 
vitamin D, is produced in the skin from 7-
dehydrocholesterol. The synthesis of vitamin D in the 
skin is the most important source of vitamin D. Vitamin 
D can also be taken through nutrition, in the diet, but it 
is present in only a few food sources, containing 
relevant levels of vitamin D. 1,25-dihydroxyvitamin 
D3 [1,25(OH)2D3] is the hormonally active form of 
vitamin D.  Novel researches show it generates a 
number of extraskeletal biological responses including 
inhibition of variety types cancer progression, effects on 
cardiovascular disorders and mediates a protection 
against a number of inflammatory, autoimmune and 
infection diseases The biological actions of 
1,25(OH)2D3 are mediated by the VDR. The genomic 
mechanism of 1,25(OH)2D3 action involves the direct 
binding of 1,25(OH)2D3 activated VDR/RXR to specific 
DNA sequences  in and around target genes resulting in 
either activation or repression of transcription [7] VDR 
modulates the expression of genes involved in immune 
function and cytokine production. The VDR and 
CYP27B1, the enzyme located in kidneys and target 
organs, are present in immune competent cells, 
bronchial and pulmonary epithelial cells, among others, 
and is up-regulated following the ligation of specific 
toll-like receptors by extracellular pathogens, 
implicating vitamin D in innate immunity. By binding 
the VDR, calcitriol induces several endogenous 
antimicrobial peptides (AMP) in monocytes, neutrophils 
and epithelial cells including cathelicidin LL-37, α-
defensin, β defensing and neutrophil gelatinase-
associated lipocalin and up-regulates nitric oxide (NO) 
synthase. Since the inflammatory response associated 
with infections such influenza, pneumonia and sepsis 
increases both clinical severity and mortality, the ability 
to reduce inflammation may allow vitamin D to 
decrease mortality and disease burden in certain 
infections. Notwithstanding the width of possible 
vitamin D application field, which being known now, 
large-scale clinical trials are still demanded. Our review 
has the aim to summarize current scientific 
understanding of Vitamin D3 effects on the 
immunological field with the focus on its capacity to 
enhance the anti-infection and anti-inflammatory 
immune reactivity. Vitamin D and Tuberculosis. 
Vitamin D has been widely studied in the 
prevention and treatment of tuberculosis. Current 
studies were focused on how calcitriol enhances the 
antimicrobial effects of macrophages and monocytes – 
important effector cells, fighting against pathogens such 
as Mycobacterium tuberculosis (MBT). Several studies 
tracked the impact of vitamin D on cytokines that 
promote anti-MTB activity and the resolution of 
infection. Suppression of antigen-stimulated pro-
inflammatory cytokines, attenuation of anti-
inflammatory cytokines, and a more rapid treatment-
induced resolution of lymphopenia and monocytosis 
associated with TB infection occurred following 
100,000 IU doses of vitamin D3 given monthly for 4 
months. Conversion of sputum smear or sputum culture 
was used to measure response to treatment in several 
studies, though only sputum culture conversion is 
independently linked to long-term risk of treatment 
failure and relapse. Also it was found  that 10,000 IU of 
vitamin D3 given daily for 6 weeks to significantly 
increase sputum smear conversion (100 % in the 
treatment group vs. 76,7 % in the placebo group, 
p=0,002). IFN-γ levels were impacted variably: 2 doses 
of vitamin D3  (600,000 IU)) led to increasing of IFN-γ 
expression , while a single 100,000 IU dose of vitamin 
D2 showed no change .  Negative results in some studies 
could be explained by variability of the Taq1 vitamin D 
receptor genotype polymorphism. It was shown that 
significantly accelerated conversion is appropriate of 
patients who have a tt genotype compared to those with 
the Tt or TT genotype. But these results were not 
confirmed by another study, where were founded no 
interaction between VDR genotype effectiveness of 
vitamin D.  Several trials show vitamin D given largely 
as an adjunctive therapy with traditional anti-
tuberculosis regimens in a variety of dose and dosing 
schedule has some impact on clearance of MBT from 
sputum in the wide number randomized controlled 
multicenter trials of patients with active tuberculosis 
infection. Patients with infection of MBT with different 
strains of tuberculosis can take benefits from Vitamin 
D3 consumption due to its effect on the clearance of 
MTB from sputum and on dampening the inflammatory 
response or anthropometric changes that may help 
tuberculosis patients recover. A significant 
microbiologic effect of vitamin D3 was indicated in 
several trials that, also, sustained by in vitro tests, where 
its antimycobacterial effects in cultured macrophages 
was shown. Antimycobacterial effect is provided 
enhances the expression of the anti-microbial peptide 
human cathelicidin (hCAP18) in cultured macrophages. 
The clinical benefit after high vitamin D3 doses 
administrating to patients does not depend of their 
vitamin D3 marked deficiency. The cause of this 
variation remains unexplained. The role of genetic 
polymorphisms in the vitamin D receptor, or in the 
multiple enzymes involved in its metabolism in vitD3 
effectiveness remains unproved. Measurement of 
calcitriol-induced antimycobacterial activity in ex vivo 
whole blood culture in future studies may help in 
understanding the functional effects of specific genetic 
polymorphisms. So, big attention will be required in 
future studies to determine mechanism of vitamin effect 
on patients with tuberculosis.  
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